The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | How will novel agents be sequenced for patients with multiple myeloma?
With the field of multiple myeloma (MM) treatment experiencing rapid progress, important questions arise surrounding the optimal sequencing of agents for patients with relapsed/refractory (R/R) disease. In this video, Suzanne Trudel, MSc, MD, University of Toronto Princess Margaret Cancer Centre, Toronto, Canada, provides her perspective on the potential strategies for sequencing novel agents, summarizing the large volume of data presented at the 2024 American Society of Clinical Oncology (ASCO) meeting. This interview took place during the 2024 ASCO Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
